XML 32 R18.htm IDEA: XBRL DOCUMENT
v3.25.3

NET LOSS PER SHARE | 9 Months Ended
--- | ---
Sep. 28, 2025
Earnings Per Share [Abstract] |
NET LOSS PER SHARE | NET LOSS PER SHARE During the thirteen and thirty-nine weeks ended September 28, 2025 and September 29, 2024, the rights, including the liquidation and dividend rights, of the holders of Class A and Class B common stock were identical, except with respect to voting. As the liquidation and dividend rights were identical, the undistributed earnings were allocated on a proportionate basis and the resulting net loss per share attributable to common stockholders were, therefore, the same for both Class A and Class B common stock on an individual or combined basis. The following table sets forth the computation of net loss per common share:
| Thirteen weeks ended |  | Thirty-nine weeks ended
| September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024
(dollar amounts in thousands) |  |  |  |  |  |  |
Numerator: |  |  |  |  |  |  |
Net loss | $ | (36,146) |  |  | $ | (20,816) |  |  | $ | (84,343) |  |  | $ | (61,343) |
Denominator: |  |  |  |  |  |  |
Weighted-average common shares outstanding—basic and diluted | 118,282,536 |  |  | 114,752,307 |  |  | 117,804,955 |  |  | 113,743,453 |
Earnings per share—basic and diluted | $ | (0.31) |  |  | $ | (0.18) |  |  | $ | (0.72) |  |  | $ | (0.54) |
The Company’s potentially dilutive securities, which include time-based vesting restricted stock units, performance stock units, contingently issuable stock and options to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be antidilutive. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
| Thirteen weeks ended |  | Thirty-nine weeks ended
| September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024
Options to purchase common stock | 14,035,191 |  |  | 13,607,548 |  |  | 14,035,191 |  |  | 13,607,548 |
Time-based vesting restricted stock units | 563,811 |  |  | 1,016,297 |  |  | 563,811 |  |  | 1,016,297 |
Performance stock units | 4,500,000 |  |  | 5,400,000 |  |  | 4,500,000 |  |  | 5,400,000 |
Contingently issuable stock | 250,000 |  |  | 506,243 |  |  | 250,000 |  |  | 506,243 |
Total common stock equivalents | 19,349,002 |  |  | 20,530,088 |  |  | 19,349,002 |  |  | 20,530,088 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration